Patient baseline characteristics
Characteristic . | Value . |
---|---|
Number of patients analyzed | 590 |
Median age, y (range) | 42 (18-68) |
Disease | |
CML | 154 (26) |
AML | 144 (24) |
MDS | 103 (17) |
RA/RARS/RCMD | 35 (6) |
RAEB | 26 (4) |
AML from MDS | 42 (7) |
ALL | 74 (13) |
NHL | 68 (12) |
MPD | 17 (3) |
CLL | 14 (2) |
HD | 6 (1) |
Multiple myeloma | 4 (1) |
CMML | 4 (1) |
LGL leukemia | 1 (0) |
NK leukemia | 1 (0) |
Stage | |
Untreated | 74 (13) |
CR1 | 222 (38) |
Second or later CR | 66 (11) |
PR | 61 (10) |
Induction failure | 85 (14) |
Relapse | 82 (14) |
Graft source | |
Bone marrow | 317 (54) |
Peripheral blood | 269 (46) |
Cord blood | 4 (1) |
Match | |
MRD | 270 (46) |
MUD | 242 (41) |
Mismatched | 78 (13) |
Conditioning | |
Cy/TBI | 567 (96) |
Bu/Cy | 22 (4) |
Other | 1 (0) |
GVHD prophylaxis | |
CnI + Mtx ± steroids | 281 (48) |
CnI + Siro ± Mtx | 198 (34) |
TCD | 68 (12) |
Other | 43 (7) |
Male recipient/female donor | 122 (21) |
CMV seropositivity | |
Recipient | 244 (41) |
Donor | 221 (37) |
Characteristic . | Value . |
---|---|
Number of patients analyzed | 590 |
Median age, y (range) | 42 (18-68) |
Disease | |
CML | 154 (26) |
AML | 144 (24) |
MDS | 103 (17) |
RA/RARS/RCMD | 35 (6) |
RAEB | 26 (4) |
AML from MDS | 42 (7) |
ALL | 74 (13) |
NHL | 68 (12) |
MPD | 17 (3) |
CLL | 14 (2) |
HD | 6 (1) |
Multiple myeloma | 4 (1) |
CMML | 4 (1) |
LGL leukemia | 1 (0) |
NK leukemia | 1 (0) |
Stage | |
Untreated | 74 (13) |
CR1 | 222 (38) |
Second or later CR | 66 (11) |
PR | 61 (10) |
Induction failure | 85 (14) |
Relapse | 82 (14) |
Graft source | |
Bone marrow | 317 (54) |
Peripheral blood | 269 (46) |
Cord blood | 4 (1) |
Match | |
MRD | 270 (46) |
MUD | 242 (41) |
Mismatched | 78 (13) |
Conditioning | |
Cy/TBI | 567 (96) |
Bu/Cy | 22 (4) |
Other | 1 (0) |
GVHD prophylaxis | |
CnI + Mtx ± steroids | 281 (48) |
CnI + Siro ± Mtx | 198 (34) |
TCD | 68 (12) |
Other | 43 (7) |
Male recipient/female donor | 122 (21) |
CMV seropositivity | |
Recipient | 244 (41) |
Donor | 221 (37) |
Values indicate number of patients (%) unless otherwise indicated. Percentages may not add to 100 because of rounding.
CML indicates chronic myelogenous leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MPD, myeloproliferative disease excluding CML and CMML; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; CMML, chronic myelomonocytic leukemia; LGL, large granular lymphocyte; NK, natural killer cell; CR, complete remission; PR, partial remission; MRD, matched related donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; GVHD, graft-versus-host disease; CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx, methotrexate; ±, with or without; Siro, sirolimus; TCD, T-cell depletion; and CMV, cytomegalovirus.